| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (NCT07156227) | National Cancer Institute (NCI) | 2027-02-13 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin (NCT07441681) | NRG Oncology | 2026-07-31 |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (NCT07195734) | National Cancer Institute (NCI) | 2026-04-24 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (NCT06532279) | NRG Oncology | 2025-06-23 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer (NCT06914999) | Emory University | 2024-12-03 |
| De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA (NCT05541016) | Mayo Clinic | 2023-02-21 |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study (NCT05136196) | National Cancer Institute (NCI) | 2022-12-06 |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (NCT05172245) | National Cancer Institute (NCI) | 2022-09-19 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer (NCT04576091) | National Cancer Institute (NCI) | 2022-07-06 |
| A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer (NCT05232851) | Mayo Clinic | 2022-06-16 |
| Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer (NCT05050162) | NRG Oncology | 2022-02-01 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin (NCT04533750) | National Cancer Institute (NCI) | 2021-12-20 |
| Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study (NCT04900623) | Jonathan Schoenfeld, MD, MPH | 2021-07-02 |
| Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy (NCT04920344) | Rutgers, The State University of New Jersey | 2021-05-19 |
| Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer (NCT04140513) | Ohio State University Comprehensive Cancer Center | 2020-10-09 |
| Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries (NCT04489212) | Mayo Clinic | 2020-10-06 |
| Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma (NCT04106362) | Jonsson Comprehensive Cancer Center | 2020-01-14 |
| Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer (NCT04162873) | University of Utah | 2019-11-27 |
| Oropharynx (OPX) Biomarker Trial (NCT06356272) | Mayo Clinic | 2019-11-15 |
| Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (NCT03811015) | National Cancer Institute (NCI) | 2019-08-16 |
| Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner (NCT03618134) | Jonsson Comprehensive Cancer Center | 2018-10-04 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (NCT03258554) | National Cancer Institute (NCI) | 2018-04-03 |
| Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer (NCT03010150) | M.D. Anderson Cancer Center | 2016-12-29 |